Company Overview
Lantern Pharma is an oncology company utilizing its AI platform, RADR, to advance precision drug development. It maintains a pipeline of targeted therapies for rare and hard-to-treat cancers.
Key Financial Figures
For the year ended December 31, 2025, Lantern Pharma did not report any top-line revenue. The company’s net loss per common share (EPS) was $(1.57) for the full year and $(0.36) for the fourth quarter.
Additional Financial Insights
Lantern finished 2025 with $10,119,224 in cash and marketable securities. Annual operating expenses totaled $17,978,494, driving a full-year net loss of $(17,119,438). Total assets were $11,035,811 compared to total liabilities of $4,501,587.
The post Lantern Pharma 2025 Financial Update first appeared on Alphastreet.
